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period of anticoagulation. In fact, the primary risk factor for
developing the postthrombotic syndrome after an initial
DVT is likely the development of recurrent DVT.2
Anticoagulation is generally prescribed for 3 months
for patients with reversible risk factors and a minimum of 6
months for those patients with permanent risk factors for
venous thrombosis3 but treatment is becoming more and
more individualized. It seems D-dimer testing4 and tests of
thrombin generation5 can also be used to guide the dura-
tion of anticoagulation. An increased period of anticoagu-
lation when these tests remain abnormal after a ”standard”
period of anticoagulation after a DVT seems to reduce
recurrent DVT and by inference could reduce severe post-
thrombotic syndrome.
The potential role of the vascular laboratory in guiding
the duration of anticoagulation is also becoming clearer.
Residual thrombosis present by ultrasound scan at the time
of discontinuation of warfarin therapy is associated with an
increased risk of recurrent VTE.6 Prandoni et al7 recently
published a randomized, multicenter, open label trial with
independent and blinded assessments of study outcomes to
evaluate the efficacy of tailoring duration of anticoagulation
based on persistence of residual venous thrombosis as de-
termined by ultrasound scan. Patients with the first episode
of proximal DVT who completed 3 months of anticoagu-
lation were assigned to receive either fixed-duration anti-
coagulation or flexible ultrasound scan-guided anticoagu-
lation. In patients assigned to the fixed-duration of
anticoagulation, those with unprovoked DVT received 3
additional months of treatment for a total of 6 months, and
those with secondary DVT had their anticoagulation dis-
continued after 3 months. Patients assigned to a flexible-
duration of anticoagulation underwent ultrasound scan
after 3 months of anticoagulation. If the veins had recana-
lized, anticoagulation was discontinued. If the veins had
not recanalized, patients were invited to undergo further
ultrasonography after 3 and 9 months if they had a second-
ary DVT and to undergo further examinations after 3, 6, 9,
15, and 20 months if they had had an unprovoked DVT.
Anticoagulation was discontinued when the veins had re-
canalized. Patients were followed for symptomatic recur-
rent VTE and major bleeding episodes.
There were 538 consecutive patients who underwent a
3-month period of anticoagulation and 530 completed the
trial. Overall, 46 of 268 patients (17.2%) allocated a fixed-
duration anticoagulation and 32 of 270 (11.9%) allocated
to flexible-duration anticoagulation developed recurrent
VTE (hazard ratio [HR] 0.64; 95% confidence interval
[CI], 0.39-0.99). If patients had unprovoked DVT, the
adjusted HR was 0.61 (95% CI, 0.36-1.02). In those with
secondary DVT, the HR ratio was 0.81 (95% CI, 0.32-
2.06). Major bleeding occurred in 0.7% of patients in the
fixed-duration group and 1.5% in the flexible-duration
group (P  .67). Overall, tailoring the duration of oral
anticoagulant therapy based on follow-up ultrasound scan
studies reduced the risk of recurrent VTE by 35% compared
to administration of warfarin therapy for a fixed-duration.The data also suggest the greatest benefit of flexible-dura-
tion warfarin therapy was in those with unprovoked or
idiopathic DVT.
Coagulation testing after a period of anticoagulation
and follow-up, vascular laboratory evaluation can perform
important functions in reducing recurrent DVT and, there-
fore, the risk of postthrombotic syndrome. Patients should
be tested for D-dimer levels and evaluated for residual DVT
by ultrasound scan in the vascular laboratory at the time of
anticipated cessation of warfarin therapy and prolonged
therapy if the veins have not recanalized or D-dimer re-
mains elevated. This should reduce recurrence of DVT and
subsequent development of postthrombotic syndrome and
venous ulcer.
The above goals for venous diagnostic testing to help
reduce venous ulcers by 50% in 10 years seem very reason-
able. The data to support them exist currently and the
needed equipment is widespread. The goals are essentially
dependent on education of primary care providers as to
what tests are available and the indication for venous test-
ing.
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THE DEFINITION OF THE VENOUS ULCER
—Joseph D. Raffetto, MD, Boston, Mass
An estimated 25 million people in the United States
have varicose veins, 2 to 6 million have more advanced
chronic venous insufficiency (swelling, skin changes), and
either active or healed chronic venous ulcers (CVU) are
seen in about 1% of the adult population, of which 500,000
are active venous ulcers (grade: high, population-based
studies).1-3 Venous ulcers usually occur at the malleolar
region both on the medial and lateral aspects of the ankle.
However, they are also known to occur on the supra-
malleolar and infra-malleolar regions of the leg and foot,
respectively. According to the revised CEAP classification
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ness defect of the skin, most frequently in the ankle region,
that fails to heal spontaneously and is sustained by chronic
venous disease (grade: low-very low, clinical observational
studies and expert opinion).4 Although this definition pro-
vides a description of a venous ulcer, it leaves much to be
interpreted. For example, venous ulcers that occur in the
ankle region may have different biologic activity and heal-
ing properties than those in other regions of the leg. The
depth of the ulcer may be different for certain full thickness
ulcers (1-2 mm depth) vs those that are 5 to 10 mm in
depth. A wound bed score (0-16, higher score better
wound bed score) that encompasses several parameters
including healing edges (wound edge effect), presence of
eschar, greatest wound depth/granulation tissue, amount
of exudates, amount of edema, peri-wound dermatitis,
peri-wound callus and or fibrosis, and a pink/red wound
bed, has demonstrated to be useful in determining wounds
that heal vs wounds that are resistant to heal (grade: low,
clinical observational study).5,6 These findings would indi-
cate that CVUs have different biologic activity, and should
not all be categorized alike as a single common venous
ulcer. Quantitative instruments to measure ulcer depth,
area, and contour are available, but not commonly used in
clinical practice, and such measurements are usually re-
served for research trials (grade: low, clinical observational
study).7,8 The importance of using quantitative instru-
ments is to standardize the evaluation of ulcers, recognize
differences in ulcers, and remove bias in studies that are
evaluating different therapies in treating CVUs. The dura-
tion and size of a CVU are important factors in determining
the potential to heal vs those ulcers that do not, also
suggesting different biological activity of CVUs (grade:
low, clinical observational studies).5,6,9,10 Venous ulcer
duration, crude size, and number of ulcers are important
parameters that have been incorporated in the venous
clinical severity score in an effort to quantify disease severity
(grade: low-very low, clinical observational studies and
expert opinion).11 It is important also to note that the
prevalence of lower extremity ulceration presenting at vas-
cular clinics that is not of venous or arterial etiology, and
which usually involves the medial lower calf, is 2.1%. These
ulcers have etiologies that include: neoplasia, chronic in-
flammation, sickle cell disease, vasculitis, rheumatoid ar-
thritis, pyoderma gangrenosum, hydroxyurea, and nonspe-
cific cause, indicating the importance of performing a
biopsy and/or hematologic/serologic evaluation in non-
healing atypical presentations of leg ulcers (grade: low,
clinical observational study).12
Published studies that evaluate adjuvant therapies in
venous ulcers, whether topical or systemic agents, or surgi-
cal procedures in conjunction with compression lack clarity
in defining a chronic venous ulcer (grade: high-low, clinical
randomized controlled trials and observational stud-
ies).13-21 Several study examples will illustrate the signifi-
cant variability of patients with CVU, inclusion criteria, and
how CVU are defined. (1) In a large randomized trial
evaluating compression plus surgery vs compression alonefor CVU (ESCHAR study), the inclusion criteria were
patients with venous ulcer (active or recently healed within
6 months) assessed by clinical examination and color ve-
nous duplex ultrasound scan, with ulcers located between
the knee andmalleoli, duration of 3 to 11months, diameter
of 1 to 5 cm, and an ankle-brachial index (ABI) of 0.85 or
higher (grade: high, clinical randomized trial).13 (2) In a
large multicenter trial evaluating human skin equivalent
(Apligraf, Organogenesis Inc, Canton,Mass), patients with
CVU defined by clinical examination and plethysmogra-
phy, and an ABI of equal to or greater than 0.65 were
randomized to compression plus human skin equivalent or
compression alone (grade: high, clinical randomized trial).
The venous ulcer area was highly variable with ulcer dura-
tions of several months to greater than 2 years.14 A fol-
low-up study of the subgroup of patients with ulcers of
greater than 1 year duration was also evaluated.15 (3) In a
small, randomized, single center trial, patients with CVUs
of venous etiology defined by clinical examination and
history, positive venous reflux, had ulcer duration ranging
from 1month to greater than 12months, with surface areas
ranging from 1.05 to 58.8 cm2, and ABI of 0.85 or higher
were randomized to compression plus extracellular matrix
small intestinal submucosa wound matrix vs compression
alone (grade: low, single center clinical observational
study).16 (4) In a randomized, placebo controlled, single
blinded study that evaluated intravenous prostaglandin E1
and venous ulcer healing (grade: low, single center clinical
observational study).17 This study enrolled patients with a
CVUby clinical examination, having an ABI of greater than
0.90, with duplex ultrasound scan evidence of venous
reflux and/or obstruction, with ulcer durations ranging
between 2 to 11 months, and ulcer areas ranging between
3 to 25 cm2. (5) In a meta-analysis of five randomized
controlled trials that investigated micronized purified fla-
vonoid fraction as an adjunct to compression in treating
CVU (grade: high, meta-analysis of five randomized clini-
cal trials).18 The patients had clinical demonstration of
venous disease and ulcers, with duplex ultrasound scan to
confirm valvular insufficiency, an ABI of greater than 0.80,
ulcer durations that ranged between 3 months and greater
than 12 months, and ulcer areas of less than 5 cm2, 5 to 10
cm2, and greater than 10 cm2. (6) In a randomized, ob-
server blinded, multicenter study, pale sulfonated shale oil
was evaluated as an adjunct to compression therapy in
treating CVU (grade: low, single center clinical observa-
tional study).19 Patients had clinical evaluations for venous
disease and duplex ultrasound scan to confirm valvular
reflux. The ABI was greater than 0.80, wound areas ranged
from less than 20 cm2 to greater than 35 cm2, and duration
of ulcer from about 3 months to more than 70 months.
These studies, although conducted in randomized and
observational methods, illustrate the significant variability
of CVU characteristics and patient inclusion criteria with
wide variability in duration and size of venous ulcers. The
wide variability in how venous ulcers are defined/repre-
sented supports the need for research in providing clear and
defined baseline ulcer parameters, and devising a venous
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ogy, pathophysiology, ulcer bed characteristics, size, and
duration, in an effort to have standardization in definition
and inclusion into studies that are assessing therapeutic
effectiveness and outcomes.
Venous ulcers are known to have significant molec-
ular changes that involve cellular alterations in growth
factors specifically transforming growth factors, mito-
gen-activated protein kinase pathways, and production
of matrix metalloproteinases (grade: low, basic science
observational studies).22-24 It has recently been demon-
strated that cytokine production and cytokine metabo-
lism are intimately associated with CVU healing (grade:
low, basic science observational study).25,26 CVUs were
evaluated for 4 weeks after compression in 30 limbs, and
tissue dermal biopsies were obtained before and after
compression and analyzed by multiplex protein assay.
Pro-inflammatory cytokine were elevated in ulcer tissue
compared to healthy tissue. Compression therapy signif-
icantly reduced pro-inflammatory cytokines (interleukin
[IL]-1, IL-1, interferon [IFN]-, IL-12p40, and
granulocyte-macrophage colony-stimulating factor [GM-
CSF]). Transforming growth factor-1 was upregulated
in ulcer tissue after compression therapy. Rapid healing
CVUs had significantly increased levels of IL-1, IL-1,
IFN-, IL-12p40, and GM-CSF before compression
therapy, and IL-1 Ra after therapy. IFN- levels signifi-
cantly decreased after therapy in the rapidly healing
patients. These data suggest that CVU healing is associ-
ated with a pro-inflammatory environment indicating
metabolically active wound tissue that has the potential
to heal. Compression therapy results in healing that is
coupled with reduced pro-inflammatory cytokine levels
and higher levels of the anti-inflammatory cytokine IL-1
Ra. Although the study is small and of short duration, it
is an important study that has begun to define the
molecular environment of active CVUs, and uses bio-
logic markers as parameters that define ulcers on a dif-
ferent level from the customary CVU duration, size, and
location. Future investigations in biologic markers hold
promise that may potentially define important biologic
differences in CVUs and promote standardization in
how CVUs are defined.
Based on current studies that have investigated the
evaluation, diagnosis, baseline ulcer characteristics, mea-
surements of CVUs, and biochemical markers, it is impor-
tant to note that venous ulcers have differential behavior,
and that the assessment of CVUs is complex with multifac-
torial parameters that may strongly influence healing po-
tential. Therefore, it is of paramount importance that
CVUs be properly defined to enable precise characteriza-
tion and standardization, which will influence study design
and inclusion in assessing natural history and epidemiology,
genetics, prognostic indicators and predictors of healing,
and clinical trials assessing different treatment modalities
that will ultimately improve healing and reduce recurrence
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NATURAL HISTORY AND PROGRESSION OF
PRIMARY CHRONIC VENOUS DISORDER
—Alun H. Davies, MD, Chung S. Lim, MD, London,
United Kingdom
Primary chronic venous disorders (CVDs) refer to
symptoms and signs of venous insufficiency of unknown
origin. Positive family history, increasing age, female gen-
der, pregnancy, and obesity are likely predisposing factors
for the development of CVD (grade: high/systemic review
of population studies).1-6 Common clinical and ultrasono-
graphic scan observations, including the finding of venous
reflux distal to competent valves, presence of competent
valves between varicosities, and venous dilatation preceding
valvular incompetence do not support the descending the-
ory of primary valvular dysfunction (grade: low/ observa-
tional and case control).7-10 These observations are more
likely to be caused by multicentric intrinsic structural and
functional abnormalities of the venous wall which are often
seen in histological specimens (grade: very low/expert’s
opinion).10,11 The ratio of type I to type III collagen is
altered12 and total elastin content is reduced13-16 in vari-
cose vein wall (grade: low/basic science-observational).
The matrix metalloproteases (MMPs) and their tissue in-
hibitors (TIMPs) balance is disrupted leading to extracel-
lular matrix degradation in varicosities (grade: low/basic
science-observational).17-19 Smoothmuscle cells have been
found to dedifferentiate from contractile to synthetic phe-
notype causing decreased contractility of varicosities
(grade: low/basic science-observational).11,20,21 Endothe-
lial cellular injury and activation increase the expression of
inflammatory markers and leukocytes recruitment in vari-
cosities (grade: low/basic science-observational).21-23
Overall, these venous wall changes are thought to contrib-
ute to the weakening, dilatation, and valvular reflux in
varicosities (grade: very low/expert’s opinion).11,18
Chronic venous insufficiency often refers to symptoms and
signs of more severe CVD such as skin changes (eg, eczema
and lipodermatosclerosis) and ulcers. Skin changes and
ulcers are thought to be caused by increased vascular per-
meability leading to extravasation of fibrinogen, 2-macro-
globulin, and erythrocytes into the dermal interstitium
(grade: low/basic science-observational).10,24-28 Degrada-
tion of the interstitial erythrocytes and protein stimulates
chronic injury and inflammatory responses. Increased ex-pression of intercellular adhesion molecule-1 on endothe-
lial cells of the microcirculation recruits macrophages, mast
cells, and lymphocytes (grade: low/basic science-observa-
tional).29,30 Leukocytes in the extracellular space are found
to surround the capillaries and postcapillary venules with
matrix proteins, forming a perivascular cuff (grade: low/
basic science-observational).25,27-32 The cuff is thought to
prevent diffusion of nutrients and oxygen into the dermis,
although it may have a protective role of providing support
to the vascular tissue from increased mechanical stress
(grade: very low/expert’s opinion).10,32 Activated leuko-
cytes are also likely to release more cytokines. The overex-
pression of transforming growth factor-1 by the intersti-
tial leukocytes has been associated with increasing severity
of CVD (grade: low/basic science-observational).33,34
Platelet-derived growth factor receptors- and ) and vas-
cular endothelial growth factor have been found to be
upregulated in the dermis of patients with CVD (grade:
low/basic science-observational).35 The proliferative abil-
ity and collagen production of fibroblasts in the venous
ulcers are reduced compared to those of normal dermis
(grade: low/basic science-observational).36-39 Alteration
to the MMP/TIMP balance such as MMP-1, MMP-2,
MMP-9, TIMP-1, and MT1-MMP has been observed in
the dermis of patients with CVD, indicating active tissue
remodeling (grade: low/basic science-observation-
al).17,34,40-42 There is still limited information on the pro-
gression of primary CVD. In a study of 116 limbs of 90
patients who had at least two duplex ultrasonographic scans
before surgery (median period of 19 months), 31 limbs
(26.7%) were found to have disease progression on the
repeat scan (grade: low/observational/longitudinal).8
Thirteen limbs (11.2%) demonstrated clinical stage pro-
gression (7 from C2-C3; 4 from C3-C4; and 2 from
C4-C6). In another study, 6% (3 of 50 limbs) of patients
with initial C2 to C4 disease developed skin damage after 5
years (grade: low/observational/longitudinal).43 The rate
of disease progression has been shown to be slower in
primary than secondary CVD.43 The mean time for ulcers
to develop from the time of the first CVDdiagnosis is about
5 years (grade: low/observational).44 In conclusion, the
understanding of the natural history and progression of
CVD remains incomplete. Current evidence suggests that
the multifactorial origin of CVD leading to tissue remod-
eling of the venous wall and dermis.
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